Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Respiratory·MeSH: Mycobacterium avium-intracellulare Infection
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| spr720 | Spero Therapeutics, Inc. (SPRO) |
Frequently asked questions
How many drugs are in development for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)?
BioSniper tracks 1 drug in development for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) across 1 company.
How many clinical trials target Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)?
There are 1 clinical trial targeting Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) tracked by BioSniper.
What is the prevalence of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)?
The estimated prevalence of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) is approximately 5.0 per 100,000 population.
Deep-dive into Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis